Oncology trial design is being rewritten in real time, and protocols written even 12 months ago are starting to look out of ...

In a step forward for patient-centered cancer research, a new pilot project reveals that 84% of participants had a positive ...

In this Q&A, Robert Hummel, chief operating officer at Suvoda, discusses how agentic AI is compressing RTSM build and ...

Clinical trials are notoriously expensive, time consuming, and risky. Failure comes at a very high cost (millions of dollars and months of development time wasted), yet studies show that the rate of ...

By fine-tuning domain-specific models with real clinical operations data — such as historical performance, feasibility ...

Despite being a cornerstone of cancer treatment advancement, clinical trials remain inaccessible for many patients because of structural, socioeconomic, and systemic barriers. In this ...

BOSTON--(BUSINESS WIRE)--Seaport Therapeutics (“Seaport” or the “Company”), a clinical-stage biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and ...

Furthermore, increasing complexity in cancer clinical trial design has led to challenges such as protocol deviations, slow enrollment leading to lengthened durations of trial, and escalating costs. By ...

Clinical trial design decisions impact costs, access, and evidence gaps, with breast cancer as the most studied disease globally. The US leads in trial activity, with China showing rapid growth, ...